RemeGen’s China Clinical Win In gMG Paves Way For Global Phase III

 
• By Dexter Jie Yan

Being the Chinese biotech’s backbone asset in the autoimmune disease area, telitacicept, a BlyS/APRIL dual targeting fusion protein, has hit its target in a China-only Phase III study in generalized myasthenia gravis. The candidate is also being investigated in global Phase III trials in systemic lupus erythematosus and Sjögren's syndrome.

Concept of Myasthenia Gravis written on sticky notes isolated on Wooden Table.
Telitacicept's domestic clinical win expected to accelerate global Phase III program for gMG • Source: Shutterstock

More from China

More from Focus On Asia